An update on diagnosis and treatment of toxic epidermal necrolysis / Novine u dijagnostici i lečenju toksične epidermalne nekrolize

1. Kandolf Sekulović L. Toksična epidermalna nekroliza. U: Šimić D, Hadžigrahić N, urednici. Hitna stanja u dermatologiji. Sarajevo: Bosnalijek; 2011. str. 45-59.Search in Google Scholar

2. Lissia M, Mulas P, Bulla A Rubino C. Toxic epidermal necrolysis (Lyell’s disease). Burns 2010;36:152-63.10.1016/j.burns.2009.06.21319766401Search in Google Scholar

3. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 2007;25:348-9.Search in Google Scholar

4. Tartarone A, Lerose R. Stevens-Johnson syndrome and toxic epidermal necrolysis: what do we know? Ther Drug Monit 2010;32:669-72.Search in Google Scholar

5. French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Allergol Int 2006;55:9-16.10.2332/allergolint.55.917075281Search in Google Scholar

6. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007;62:1439-44.10.1111/j.1398-9995.2007.01553.x17983378Search in Google Scholar

7. Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y,Bork K, et al. An algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010;88:60-8.10.1038/clpt.2009.25220375998Search in Google Scholar

8. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44.10.1038/sj.jid.570103317805350Search in Google Scholar

9. Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987;123:1171-3.10.1001/archderm.1987.01660330082014Search in Google Scholar

10. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102:4134-9.10.1073/pnas.040950010255481215743917Search in Google Scholar

11. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.10.1038/428486a15057820Search in Google Scholar

12. Aguiar D, Pazo R, Durán I, Terrasa J, Arrivi A, Manzano H, et al. Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neurooncol 2004;66:345-50.10.1023/B:NEON.0000014538.31561.bcSearch in Google Scholar

13. Nassif A, Bensussan A, Dorothe´e G, Mami-Chouaib F, Bachot N, Bagot M, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002;118:728-33.10.1046/j.1523-1747.2002.01622.x11918724Search in Google Scholar

14. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004;114:1209-15.10.1016/j.jaci.2004.07.047Search in Google Scholar

15. Roujeau J. Immune mechanisms in drug allergy. Allergol Int 2006;55:27-33.10.2332/allergolint.55.27Search in Google Scholar

16. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004;123:850-5.10.1111/j.0022-202X.2004.23439.xSearch in Google Scholar

17. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3.10.1126/science.282.5388.490Search in Google Scholar

18. Ito K, Hara H, Okada T, Shimojima H, Suzuki H. Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fasligand expression. Clin Exp Dermatol 2004;29:679-80.10.1111/j.1365-2230.2004.01635.xSearch in Google Scholar

19. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003;162:1515-20.10.1016/S0002-9440(10)64284-8Search in Google Scholar

20. Dylewski ML, Prelack K, Keaney T, Sheridan RL. Asymptomatic hyperamylasemia and hyperlipasemia in pediatric patients with toxic epidermal necrolysis. J Burn Care Res 2010; 31:292-6.10.1097/BCR.0b013e3181d0f44820182382Search in Google Scholar

21. Wong KC, Kennedy PJ, Lee S. Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol 1999;40:131-4.10.1046/j.1440-0960.1999.00342.x10439522Search in Google Scholar

22. French LE, Prins C. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. In: Bolognia JL, ed. Dermatology. 2nd ed. St. Louis: Elsevier; 2008. p. 287-300.Search in Google Scholar

23. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.10.1046/j.1523-1747.2000.00061.x10951229Search in Google Scholar

24. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use ofSCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004;140:890-2.10.1001/archderm.140.7.89015262712Search in Google Scholar

25. Imahara SD, Holmes JH, Heimbach DM, Engrav LE, Honari SH, Klein M, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res. 2006;27:270-5.10.1097/01.BCR.0000216532.71360.9B16679892Search in Google Scholar

26. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005;153:241-53.10.1111/j.1365-2133.2005.06721.x16086734Search in Google Scholar

27. Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23:87-9.10.1097/00004630-200203000-0000411882797Search in Google Scholar

28. Fromowitz JS, Ramos-Caro FA, Flowers FP. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol. 2007;46:1092-4.10.1111/j.1365-4632.2007.03277.x17910723Search in Google Scholar

29. Coss-Bu JA, Jefferson LS, Levy ML, Walding D, David Y, Klish WJ. Nutrition requirements in patients with toxic epidermal necrolysis. Nutr Clin Pract. 1997;12:81-4.10.1177/0115426597012002819155407Search in Google Scholar

30. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33-40.10.1016/j.jaad.2007.08.03917919775Search in Google Scholar

31. Herndon D. Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg. 1995;180:340-2.Search in Google Scholar

32. Hanken I, Schimmer M, Sander CA. Basic measures and systemic medical treatment of patients with toxic epidermal necrolysis. J Dtsch Dermatol Ges. 2010;8:341-6.10.1111/j.1610-0387.2009.07289_supp.xSearch in Google Scholar

33. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139:26-32.10.1001/archderm.139.1.2612533160Search in Google Scholar

34. Stella M, Clemente A, Bollero D, Risso D, Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach: a retrospective analysis. Burns. 2007;33:452-9.10.1016/j.burns.2006.08.01417475410Search in Google Scholar

35. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil. 2004;25:81-8.Search in Google Scholar

36. Chaidemenos GC, Chrysomallis F, Sombolos K, Mourellou O, Ioannides D, Papakonstantinou M. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol. 1997;36:218-21.10.1046/j.1365-4362.1997.00192.x9159011Search in Google Scholar

37. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg. 2005;58:504-10.10.1016/j.bjps.2004.12.007Search in Google Scholar

38. Mladenović T, Kostić K, Kozarski J, Panišić M, Begović V, Kandolf Sekulović L, i sar. Toksična epidermalna nekroliza - Syndrom Lyell. U: Zbornik rezimea XV Beogradski dermatološki dani; 2010 Novembar 12-13; Beograd (Srbija). Beograd: Udruženje dermatovenerologa Srbije; 2010. p. 53 (PS-14).Search in Google Scholar

39. Reese D, Henning JS, Rockers K, Ladd D, Gilson R. Cyclosporine for SJS/TEN: a case series and review of the literature. Cutis. 2011;87:24-9.Search in Google Scholar

40. Arévalo JM, Lorente JA, González-Herrada C, Jiménez- Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48:473-8.10.1097/00005373-200003000-00017Search in Google Scholar

41. Gubinelli E, Canzona F, Tonanzi T, Raskovic D, Didona B. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol. 2009;36:150-3.10.1111/j.1346-8138.2009.00616.xSearch in Google Scholar

42. Al-Shouli S, Abouchala N, Bogusz MJ, Al Tufail M, Thestrup-Pedersen K. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol. 2005;85:534-5.Search in Google Scholar

43. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998; 352:1586-9. 10.1016/S0140-6736(98)02197-7Search in Google Scholar